Balance Sheet
Cash Flow Statement
Amortization of Deferred ChargesAmortizatization of IntangiblesCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Accured ExpensesChange in CashChange in ReceivablesDepreciation & Amortization (CF)Free Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeSales of Property, Plant and EquipmentShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Cidara Therapeutics (CDTX) Capital Expenditures: 2014-2024

Historic Capital Expenditures for Cidara Therapeutics (CDTX) over the last 11 years, with Dec 2024 value amounting to $129,000.

  • Cidara Therapeutics' Capital Expenditures fell 81.75% to $23,000 in Q3 2024 from the same period last year, while for Sep 2024 it was $307,000, marking a year-over-year decrease of 8.63%. This contributed to the annual value of $129,000 for FY2024, which is 74.46% down from last year.
  • As of FY2024, Cidara Therapeutics' Capital Expenditures stood at $129,000, which was down 74.46% from $505,000 recorded in FY2023.
  • Cidara Therapeutics' 5-year Capital Expenditures high stood at $505,000 for FY2023, and its period low was $78,000 during FY2021.
  • In the last 3 years, Cidara Therapeutics' Capital Expenditures had a median value of $129,000 in 2024 and averaged $250,667.
  • Its Capital Expenditures has fluctuated over the past 5 years, first spiked by 431.43% in 2020, then tumbled by 74.46% in 2024.
  • Cidara Therapeutics' Capital Expenditures (Yearly) stood at $186,000 in 2020, then tumbled by 58.06% to $78,000 in 2021, then soared by 51.28% to $118,000 in 2022, then soared by 327.97% to $505,000 in 2023, then plummeted by 74.46% to $129,000 in 2024.